Titlebook: Leading Pharmaceutical Innovation; How to Win the Life Oliver Gassmann,Alexander Schuhmacher,Gerrit Reepm Book 2018Latest edition Springer

厭惡

MUTED

Fortify

Insul島

Innovation: Key to Success in the Pharmaceutical Industry,ustomer and regulatory bodies in the development of new medicines, and the vanishing of easy targets. An overview is given of established and emerging pharma companies, the cost structures for pharma innovation, and the nature of the productivity gap. We describe the blockbuster imperative and the p

Ethics

The Industry Challenge: Who Would Want to Be in This Business?,ors. We employ Porter’s Five-Forces industry analysis to examine the power of suppliers and buyers, potential competitors, the threat of substitute products, and rivalry among established companies. Regulators are also discussed, as they constitute a key stakeholder in the industry. We present key c

Extricate

The Science and Technology Challenge: How to Find New Drugs,ral new discovery and development technologies. The rise of the biotech industry is the most obvious one, but new approaches in target discovery, high-throughput screening, combinatorial chemistry, hit and lead generation, bioinformatics, big data, proteomics and pharmacogenetics are also radically

Infirm

The Pipeline Challenge: How to Organize Innovation, research and development phases are highly regulated and defined with precision—a prime example of a stage-gate process. Given the long duration of the development of a new drug, and the increasing R&D costs per drug on average, the industry faces unfavorable innovation economics also known as “the

貝雷帽

Fluctuate

我要威脅

The Internationalization Challenge: Where to Access Innovation,ology and talent wherever it emerges. Apart from the established centers of innovation in the United States, Europe and Japan, India, China and Singapore are rising attractors for global life science R&D. China as a pharma market and host of pharma R&D is highlighted as a case study, both from the a